These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8950895)

  • 1. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin.
    Corsini A; Pazzucconi F; Pfister P; Paoletti R; Sirtori CR
    Lancet; 1996 Dec; 348(9041):1584. PubMed ID: 8950895
    [No Abstract]   [Full Text] [Related]  

  • 2. [Fluvastatin].
    Teramoto T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():587-91. PubMed ID: 11347136
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro.
    Rogler G; Lackner KJ; Schmitz G
    Am J Cardiol; 1995 Jul; 76(2):114A-116A. PubMed ID: 7604784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-apoptotic effect of fluvastatin on human smooth muscle cells.
    Buemi M; Allegra A; Senatore M; Marino D; Medici MA; Aloisi C; Di Pasquale G; Corica F
    Eur J Pharmacol; 1999 Apr; 370(2):201-3. PubMed ID: 10323270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct effects of statins on the vascular wall.
    Corsini A; Pazzucconi F; Arnaboldi L; Pfister P; Fumagalli R; Paoletti R; Sirtori CR
    J Cardiovasc Pharmacol; 1998 May; 31(5):773-8. PubMed ID: 9593078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term effects of fluvastatin, a hydroxylmethylglutaryl-coenzyme A reductase inhibitor, on coagulation and the fibrinolytic system in patients with hypercholesterolemia.
    Saito M; Asakura H; Morishita E; Yamazaki M; Matsuda T
    Int J Hematol; 1999 Jun; 69(4):274-6. PubMed ID: 10407589
    [No Abstract]   [Full Text] [Related]  

  • 7. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
    Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvastatin reduces endothelin secretion of cultured human umbilical vein endothelial cells.
    Mueck AO; Seeger H; Lippert TH
    Eur J Clin Pharmacol; 1999 Nov; 55(9):625-6. PubMed ID: 10638389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease.
    Bevilacqua M; Bettica P; Milani M; Vago T; Rogolino A; Righini V; Santoli E; Norbiato G
    Am J Cardiol; 1997 Jan; 79(1):84-7. PubMed ID: 9024745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells.
    Ito T; Ikeda U; Shimpo M; Ohki R; Takahashi M; Yamamoto K; Shimada K
    Cardiovasc Drugs Ther; 2002 Mar; 16(2):121-6. PubMed ID: 12090904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluvastatin enhances apoptosis in cytokine-stimulated vascular smooth muscle cells.
    Takahashi M; Ogata Y; Okazaki H; Takeuchi K; Kobayashi E; Ikeda U; Shimada K
    J Cardiovasc Pharmacol; 2002 Feb; 39(2):310-7. PubMed ID: 11791017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mevalonate is essential for growth of porcine and human vascular smooth muscle cells in vitro.
    Rogler G; Lackner KJ; Schmitz G
    Basic Res Cardiol; 1995; 90(6):443-50. PubMed ID: 8773189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of fluvastatin on degradation of apolipoprotein B by a radical reaction in human plasma.
    Aoki S; Ikeda K; Yamamura M; Kojo S
    Biol Pharm Bull; 2001 Feb; 24(2):123-6. PubMed ID: 11217077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation.
    Horiuchi M; Cui TX; Li Z; Li JM; Nakagami H; Iwai M
    Circulation; 2003 Jan; 107(1):106-12. PubMed ID: 12515751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells.
    Hayashi K; Kurokawa J; Nomura S; Kuga Y; Ohkura Y; Kajiyama G
    Biochim Biophys Acta; 1993 Apr; 1167(2):223-5. PubMed ID: 8466953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of fluvastatin on plasma fibrinogen levels.
    Rizos E; Miltiadous G; Elisaf M
    Curr Med Res Opin; 2002; 18(3):154-5. PubMed ID: 12094825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvastatin and fluvastatin extended release: a clinical and safety profile.
    Asberg A; Holdaas H
    Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):641-52. PubMed ID: 15350166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells.
    Ikeda U; Shimpo M; Ohki R; Inaba H; Takahashi M; Yamamoto K; Shimada K
    Hypertension; 2000 Sep; 36(3):325-9. PubMed ID: 10988259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluvastatin prevents vascular hyperplasia by inhibiting phenotype modulation and proliferation through extracellular signal-regulated kinase 1 and 2 and p38 mitogen-activated protein kinase inactivation in organ-cultured artery.
    Sakamoto K; Murata T; Chuma H; Hori M; Ozaki H
    Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):327-33. PubMed ID: 15591221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression.
    Ferri N; Granata A; Pirola C; Torti F; Pfister PJ; Dorent R; Corsini A
    Mol Pharmacol; 2008 Jul; 74(1):144-53. PubMed ID: 18413661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.